Aldoss Ibrahim T, Weisenburger Dennis D, Fu Kai, Chan Wing C, Vose Julie M, Bierman Philip J, Bociek R Gregory, Armitage James O
Creighton University Medical Center, NE 68131-2197, USA.
Oncology (Williston Park). 2008 Nov 30;22(13):1508-17.
Burkitt lymphoma is a unique B-cell malignancy with a high proliferation rate and characteristic genetic changes involving the c-myc oncogene. Burkitt lymphoma is common in children but also occurs in adults, where distinction from diffuse large B-cell lymphoma may pose a problem. The development of brief, very intensive chemotherapy regimens has led to a very high cure rate in children with Burkitt lymphoma. The use of these regimens in adults, often in combination with the antibody rituximab (Rituxan), has also made the cure of a majority of adults possible. Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone, rituximab). Prompt diagnosis and initiation of appropriate therapy with attention to the possibility of tumor lysis syndrome are necessary for optimal results.
伯基特淋巴瘤是一种独特的B细胞恶性肿瘤，增殖率高，具有涉及c-myc癌基因的特征性基因改变。伯基特淋巴瘤在儿童中常见，但也发生于成人，在成人中与弥漫性大B细胞淋巴瘤的区分可能存在问题。简短、高强度化疗方案的发展已使伯基特淋巴瘤患儿的治愈率非常高。这些方案在成人中的应用，通常与抗体利妥昔单抗（美罗华）联合使用，也使大多数成人得以治愈。成人伯基特淋巴瘤不能用治疗弥漫性大B细胞淋巴瘤的常用方案如CHOP-R（环磷酰胺、盐酸阿霉素、长春新碱[安可平]、泼尼松、利妥昔单抗）有效治疗。为获得最佳结果，必须迅速诊断并开始适当治疗，同时注意肿瘤溶解综合征的可能性。
